Notably, patients harboring TP53 alterations derived clinical benefit from adjuvant lenvatinib following curative surgery. In conclusion, TDS enables effective identification of MRD-associated genomic alterations and stratifies HCC patients who may benefit from adjuvant lenvatinib, providing a molecular basis for personalized postoperative management.

1 day ago

Journal • Real-world evidence • Tumor mutational burden

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)

TP53 mutation

Lenvima (lenvatinib)

Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma. (PubMed, World J Hepatol)

Sintilimab plus lenvatinib showed heterogeneous efficacy in HCC. High LINC01554 expression, elevated CD4+ Tcm cells, and solitary tumors may serve as predictive biomarkers for prolonged disease control.

2 days ago

Journal • IO biomarker

CD4 (CD4 Molecule) • CUX1 (cut like homeobox 1) • DFNB31 (Deafness, Autosomal Recessive 31) • FANCD2 (FA Complementation Group D2)

Tyvyt (sintilimab) • Lenvima (lenvatinib)

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer (clinicaltrials.gov)

P3, N=450, Not yet recruiting, Evergreen Therapeutics, Inc. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

4 days ago

Trial completion date • Trial primary completion date • Head-to-Head

Keytruda (pembrolizumab) • Lenvima (lenvatinib)

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov)

P2, N=28, Not yet recruiting, Evergreen Therapeutics, Inc. | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

4 days ago

Trial completion date • Trial primary completion date

Keytruda (pembrolizumab) • Lenvima (lenvatinib)

Neuro-oncological ventral antigen 1 regulates liver cancer stem cell properties and Lenvatinib resistance via targeting SOX4. (PubMed, Cancer Cell Int)

Moreover, knocking down SOX4 could reverse the NOVA1 overexpression-mediated desensitization of HCC cells to Lenvatinib-induced cell apoptosis. In summary, this investigation indicates the essential role of NOVA1 self-renew of CSCs and tumorigenesis in the liver, suggesting it as an optimal HCC therapeutic target.

4 days ago

Journal

SOX4 (SRY-Box Transcription Factor 4)

Lenvima (lenvatinib)

Activation of YBX1 and JAK2/STAT3 pathways by RIOK1 increases lenvatinib resistance in hepatocellular carcinoma cells. (PubMed, Biochim Biophys Acta Mol Cell Res)

Tumor volume, apoptosis, KI67, YBX1, and JAK2/STAT3 phosphorylation levels were reduced in tumor tissue after RIOK1 knockdown and increased after further YBX1 overexpression. Overall, RIOK1 activates the JAK2/STAT3 pathway by promoting YBX1 phosphorylation, leading to HCC progression and lenvatinib resistance.

5 days ago

Journal

YBX1 (Y-Box Binding Protein 1)

Lenvima (lenvatinib)

LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov)

P1/2, N=30, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2025

6 days ago

Trial completion • Trial completion date

Lenvima (lenvatinib) • Halaven (eribulin mesylate)

Lenvatinib-resistant liver cancer-derived HSP90α-containing extracellular vesicles enhance drug resistance via macrophage CXCL8 secretion. (PubMed, Immunol Lett)

In conclusion, our study demonstrated that EVs containing HSP90α, derived from lenvatinib-resistant liver cancer cells, can promote EMT and drug resistance in HCC cells by stimulating CXCL8 secretion from macrophages. This finding may provide new insights and strategies to overcome lenvatinib resistance in the future.

7 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • VIM (Vimentin) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • TLR2 (Toll Like Receptor 2)

Lenvima (lenvatinib)

Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma. (PubMed, Auris Nasus Larynx)

The patient was initially diagnosed with T4bN1bM1 and experienced disease progression following surgery and lenvatinib treatment. This possibility is supported by reliable evidence for the use of BRAF plus MEK inhibitor for brain metastasis from BRAF-mutated malignant melanoma. We conclude that encorafenib plus binimetinib treatment for brain metastasis from BRAF-mutated thyroid cancer is a safe and effective treatment choice.

7 days ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600

Lenvima (lenvatinib) • Mektovi (binimetinib) • Braftovi (encorafenib)

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov)

P2, N=408, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

8 days ago

Trial completion

Keytruda (pembrolizumab) • Erbitux (cetuximab) • paclitaxel • docetaxel • Lenvima (lenvatinib) • capecitabine